Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

CD20-positive Non-Hodgkin Lymphoma

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China
Contact: Study coordinator (Keshu Zhou, MD) · drzhouks77@163.com
Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
Contact: Study coordinator (Chunyan Ji, MD) · jichunyan@sdu.edu.cn
Contact: Study coordinator (Fei Lu, MD) · lufeisdu2@163.com
Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Chunkang Chang, MD) · Changchunkang7010@aliyun.com · 86-13764643870
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Junyuan Qi, MD. PHD) · qijy@ihcams.ac.cn
Contact: Study coordinator (Mingyuan Sun, MD) · sunmingyuan@ihcams.ac.cn

מובילי המחקר

Junyuan Qi, MD, PHD
Principal Investigator
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences